Ascension St John Hospital
- Type
- Teaching hospital
- Where
- Detroit, MI
- Medicare CCN
- 230165
- Received
- $873,492 in 196 records, 2024 ($38,787 general, $834,704 research)
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2024 | General payment | 20 | $38,787 |
| 2024 | Research payment | 176 | $834,704 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| PFIZER INC. | 47 | $381,896 | 2024 |
| Medtronic, Inc. | 69 | $232,412 | 2024 |
| Genentech, Inc. | 11 | $75,396 | 2024 |
| Genetesis, Inc. | 6 | $52,069 | 2024 |
| Impulse Dynamics (USA) Inc. | 20 | $50,997 | 2024 |
| Eli Lilly and Company | 2 | $15,060 | 2024 |
| Penumbra, Inc. | 10 | $10,660 | 2024 |
| Biogen, Inc. | 1 | $10,515 | 2024 |
| ERBE USA Inc | 2 | $7,000 | 2024 |
| Boston Scientific Corporation | 2 | $7,000 | 2024 |
| Regeneron Healthcare Solutions, Inc. | 3 | $6,000 | 2024 |
| ABBVIE INC. | 2 | $4,000 | 2024 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $4,000 | 2024 |
| Olympus Corporation of the Americas | 1 | $4,000 | 2024 |
| Gilead Sciences, Inc. | 3 | $2,683 | 2024 |
| ACUMED LLC | 1 | $2,000 | 2024 |
| Olympus America Inc. | 2 | $2,000 | 2024 |
| Endologix LLC | 1 | $1,950 | 2024 |
| BIOTRONIK INC. | 7 | $1,562 | 2024 |
| Celgene Corporation | 1 | $1,500 | 2024 |
| AngioDynamics, Inc. | 1 | $577 | 2024 |
| Baxter Healthcare | 1 | $159 | 2024 |
| Abbott Laboratories | 1 | $50 | 2024 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 176 | $834,704 |
| Grant | 7 | $19,000 |
| Space rental or facility fees (teaching hospital only) | 9 | $12,050 |
| Honoraria | 1 | $5,000 |
| Education | 1 | $2,000 |
| Long term medical supply or device loan | 1 | $577 |
| Debt forgiveness | 1 | $159 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2024-12-31 | PFIZER INC. | $22,235 | Research payment | Cash or cash equivalent | PREVNAR 20 Biological, VACCINES | A PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A | 2024 |
| 2024-12-18 | Medtronic, Inc. | $19,599 | Research payment | Cash or cash equivalent | SYMPLICITY G3 Device, Renal Denervation System | SPYRAL AFFIRM | 2024 |
| 2024-12-16 | Medtronic, Inc. | $1,064 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | SMART Trial | 2024 |
| 2024-12-16 | Medtronic, Inc. | $1,064 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | SMART Trial | 2024 |
| 2024-12-11 | Medtronic, Inc. | $6,163 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | EXPAND II | 2024 |
| 2024-12-09 | Genentech, Inc. | $24,150 | Research payment | Cash or cash equivalent | Tecentriq Biological, BioOncology | A PHASE III, RANDOMIZED, DOUBLE-BLIND STUDY OF TIRA PLUS ATEZO IN ADJUVANT NSCLC | 2024 |
| 2024-12-09 | Genentech, Inc. | $18,950 | Research payment | Cash or cash equivalent | Tecentriq Biological, BioOncology | A PHASE III, RANDOMIZED, DOUBLE-BLIND STUDY OF TIRA PLUS ATEZO IN ADJUVANT NSCLC | 2024 |
| 2024-12-05 | PFIZER INC. | $25,836 | Research payment | Cash or cash equivalent | PREVNAR 20 Biological, VACCINES | A PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A | 2024 |
| 2024-12-03 | Medtronic, Inc. | $1,625 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | Optimize Pro | 2024 |
| 2024-12-03 | Medtronic, Inc. | $1,625 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | Optimize Pro | 2024 |
| 2024-11-27 | Impulse Dynamics (USA) Inc. | $75 | Research payment | Cash or cash equivalent | OPTIMIZER Device, Cardiovascular Device | Post Approval Study (PAS) of the OPTIMIZER Smart and CCM Therapy | 2024 |
| 2024-11-13 | Penumbra, Inc. | $300 | Research payment | Cash or cash equivalent | Indigo System Device, Peripheral Intervention | STRIKE-PE | 2024 |
| 2024-11-08 | PFIZER INC. | $7,606 | Research payment | Cash or cash equivalent | PREVNAR 20 Biological, VACCINES | A PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A | 2024 |
| 2024-11-08 | Eli Lilly and Company | $9 | Research payment | In-kind items and services | STUDY OF LOXO-305 VERSUS INVESTIGATOR'S CHOICE (IDELAR OR BR) IN PATIENTS WITH PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LE | 2024 | |
| 2024-11-06 | Celgene Corporation | $1,500 | Research payment | Cash or cash equivalent | Celgene Connect Myeloid Disease Registry | 2024 | |
| 2024-11-06 | Impulse Dynamics (USA) Inc. | $300 | Research payment | Cash or cash equivalent | OPTIMIZER Device, Cardiovascular Device | Assessment of CCM in HF With Higher Ejection Fraction (AIM HIGHer) | 2024 |
| 2024-10-22 | PFIZER INC. | $1,413 | Research payment | Cash or cash equivalent | A PHASE 12 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCI | 2024 | |
| 2024-10-21 | Medtronic, Inc. | $500 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | EXPAND II | 2024 |
| 2024-10-21 | Medtronic, Inc. | $500 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | EXPAND II | 2024 |
| 2024-10-19 | PFIZER INC. | $11,784 | Research payment | Cash or cash equivalent | PREVNAR 20 Biological, VACCINES | A PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A | 2024 |
| 2024-10-10 | Medtronic, Inc. | $1,860 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | TAVR Low Risk | 2024 |
| 2024-10-10 | Medtronic, Inc. | $1,860 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | TAVR Low Risk | 2024 |
| 2024-10-10 | Medtronic, Inc. | $1,791 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | CoreValve SURTAVI | 2024 |
| 2024-10-10 | Medtronic, Inc. | $1,791 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | CoreValve SURTAVI | 2024 |
| 2024-10-08 | PFIZER INC. | $350 | Research payment | Cash or cash equivalent | AN INTERVENTIONAL PHASE 23 ADAPTIVE MULTICENTER RANDOMIZED DOUBLEBLIND STUDY TO INVESTIGATE EFFICACY AND SAFETY OF ORAL | 2024 | |
| 2024-09-30 | Impulse Dynamics (USA) Inc. | $1,469 | Research payment | Cash or cash equivalent | OPTIMIZER Device, Cardiovascular Device | Assessment of CCM in HF With Higher Ejection Fraction (AIM HIGHer) | 2024 |
| 2024-09-30 | Impulse Dynamics (USA) Inc. | $200 | Research payment | Cash or cash equivalent | OPTIMIZER Device, Cardiovascular Device | Post Approval Study (PAS) of the OPTIMIZER Smart and CCM Therapy | 2024 |
| 2024-09-28 | PFIZER INC. | $11,726 | Research payment | Cash or cash equivalent | PREVNAR 20 Biological, VACCINES | A PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A | 2024 |
| 2024-09-26 | Medtronic, Inc. | $10,500 | Research payment | Cash or cash equivalent | SYMPLICITY G3 Device, Renal Denervation System | SPYRAL AFFIRM | 2024 |
| 2024-09-26 | Medtronic, Inc. | $1,000 | Research payment | Cash or cash equivalent | SYMPLICITY G3 Device, Renal Denervation System | SPYRAL AFFIRM | 2024 |
| 2024-09-25 | Medtronic, Inc. | $56,981 | Research payment | Cash or cash equivalent | SYMPLICITY G3 Device, Renal Denervation System | SPYRAL AFFIRM | 2024 |
| 2024-09-19 | Medtronic, Inc. | $3,108 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | EXPAND II | 2024 |
| 2024-09-19 | Medtronic, Inc. | $3,108 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | EXPAND II | 2024 |
| 2024-09-17 | Abbott Laboratories | $50 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2024 | ||
| 2024-09-12 | Medtronic, Inc. | $2,419 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | SMART Trial | 2024 |
| 2024-09-12 | Medtronic, Inc. | $2,419 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | SMART Trial | 2024 |
| 2024-09-09 | Medtronic, Inc. | $13,000 | Research payment | Cash or cash equivalent | SYMPLICITY G3 Device, Renal Denervation System | SPYRAL AFFIRM | 2024 |
| 2024-09-06 | Medtronic, Inc. | $875 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | EXPAND II | 2024 |
| 2024-09-06 | Medtronic, Inc. | $875 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | EXPAND II | 2024 |
| 2024-09-04 | PFIZER INC. | $27,890 | Research payment | Cash or cash equivalent | PREVNAR 20 Biological, VACCINES | A PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A | 2024 |
| 2024-08-29 | Medtronic, Inc. | $500 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | EXPAND II | 2024 |
| 2024-08-29 | Medtronic, Inc. | $500 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | EXPAND II | 2024 |
| 2024-08-27 | PFIZER INC. | $3,500 | Research payment | Cash or cash equivalent | ABRYSVO Biological, VACCINES | A PHASE 3 MASTER PROTOCOL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREF | 2024 |
| 2024-08-23 | Impulse Dynamics (USA) Inc. | $124 | Research payment | Cash or cash equivalent | OPTIMIZER Device, Cardiovascular Device | Assessment of CCM in HF With Higher Ejection Fraction (AIM HIGHer) | 2024 |
| 2024-08-22 | PFIZER INC. | $4,825 | Research payment | Cash or cash equivalent | AN INTERVENTIONAL PHASE 23 ADAPTIVE MULTICENTER RANDOMIZED DOUBLEBLIND STUDY TO INVESTIGATE EFFICACY AND SAFETY OF ORAL | 2024 | |
| 2024-08-21 | Penumbra, Inc. | $96 | Research payment | Cash or cash equivalent | Indigo System Device, Peripheral Intervention | STRIKE-PE | 2024 |
| 2024-08-20 | Genetesis, Inc. | $14,510 | Research payment | Cash or cash equivalent | CardioFlux Device, Cardiovascular Diagnostic | MCG as a Noninvasive Diagnostic Strategy for Suspected INOCA (MICRO2) | 2024 |
| 2024-08-14 | PFIZER INC. | $6,145 | Research payment | Cash or cash equivalent | A PHASE 12 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCI | 2024 | |
| 2024-08-14 | Genentech, Inc. | $4,745 | Research payment | Cash or cash equivalent | MyTACTIC Targeting Actionable Mutation Study in Cancer US PIIa multicenter nonrandomized open LBL | 2024 | |
| 2024-08-13 | Impulse Dynamics (USA) Inc. | $869 | Research payment | Cash or cash equivalent | OPTIMIZER Device, Cardiovascular Device | Assessment of CCM in HF With Higher Ejection Fraction (AIM HIGHer) | 2024 |
| 2024-08-08 | Medtronic, Inc. | $1,000 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | EXPAND II | 2024 |
| 2024-08-08 | Medtronic, Inc. | $1,000 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | EXPAND II | 2024 |
| 2024-08-08 | Medtronic, Inc. | $500 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | SMART Trial | 2024 |
| 2024-08-08 | Medtronic, Inc. | $500 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | SMART Trial | 2024 |
| 2024-08-07 | Impulse Dynamics (USA) Inc. | $220 | Research payment | Cash or cash equivalent | OPTIMIZER Device, Cardiovascular Device | Assessment of CCM in HF With Higher Ejection Fraction (AIM HIGHer) | 2024 |
| 2024-08-05 | Medtronic, Inc. | $200 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | TAVR Low Risk | 2024 |
| 2024-08-05 | Medtronic, Inc. | $200 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | TAVR Low Risk | 2024 |
| 2024-08-01 | Genentech, Inc. | $5,640 | Research payment | Cash or cash equivalent | MorningSun | 2024 | |
| 2024-07-26 | PFIZER INC. | $1,616 | Research payment | Cash or cash equivalent | A PHASE 12 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCI | 2024 | |
| 2024-07-24 | PFIZER INC. | $960 | Research payment | Cash or cash equivalent | AN INTERVENTIONAL PHASE 23 ADAPTIVE MULTICENTER RANDOMIZED DOUBLEBLIND STUDY TO INVESTIGATE EFFICACY AND SAFETY OF ORAL | 2024 | |
| 2024-07-22 | Medtronic, Inc. | $150 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | EXPAND II | 2024 |
| 2024-07-19 | Impulse Dynamics (USA) Inc. | $500 | Research payment | Cash or cash equivalent | OPTIMIZER Device, Cardiovascular Device | Post Approval Study (PAS) of the OPTIMIZER Smart and CCM Therapy | 2024 |
| 2024-07-17 | Medtronic, Inc. | $840 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | CoreValve SURTAVI | 2024 |
| 2024-07-17 | Medtronic, Inc. | $840 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | CoreValve SURTAVI | 2024 |
| 2024-07-16 | PFIZER INC. | $3,248 | Research payment | Cash or cash equivalent | A PHASE 12 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCI | 2024 | |
| 2024-07-16 | Medtronic, Inc. | $1,267 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | TAVR Low Risk | 2024 |
| 2024-07-16 | Medtronic, Inc. | $1,267 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | TAVR Low Risk | 2024 |
| 2024-07-16 | Medtronic, Inc. | $875 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | SMART Trial | 2024 |
| 2024-07-16 | Medtronic, Inc. | $875 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | SMART Trial | 2024 |
| 2024-07-15 | Penumbra, Inc. | $1,806 | Research payment | Cash or cash equivalent | Indigo System Device, Peripheral Intervention | STRIKE-PE | 2024 |
| 2024-07-15 | Penumbra, Inc. | $953 | Research payment | Cash or cash equivalent | Indigo System Device, Peripheral Intervention | STRIKE-PE | 2024 |
| 2024-07-11 | PFIZER INC. | $18,293 | Research payment | Cash or cash equivalent | PREVNAR 20 Biological, VACCINES | A PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A | 2024 |
| 2024-07-11 | Genetesis, Inc. | $1,463 | Research payment | Cash or cash equivalent | CardioFlux Device, Cardiovascular Diagnostic | MCG for Suspected INOCA Confirmed by Thermodilution-Derived CFR (Micro(T)) | 2024 |
| 2024-07-09 | Gilead Sciences, Inc. | $1,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2024 | ||
| 2024-07-09 | Gilead Sciences, Inc. | $1,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2024 | ||
| 2024-06-28 | PFIZER INC. | $1,897 | Research payment | Cash or cash equivalent | A PHASE 12 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCI | 2024 | |
| 2024-06-26 | PFIZER INC. | $632 | Research payment | Cash or cash equivalent | A PHASE 12 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCI | 2024 | |
| 2024-06-13 | Gilead Sciences, Inc. | $683 | Research payment | Cash or cash equivalent | Sunlenca Drug, HIV | A Phase 2 Randomized, Open Label, Active Controlled Study Evaluating the Safety and Efficacy of Long-acting Capsid Inhib | 2024 |
| 2024-06-11 | Impulse Dynamics (USA) Inc. | $1,833 | Research payment | Cash or cash equivalent | OPTIMIZER Device, Cardiovascular Device | Assessment of CCM in HF With Higher Ejection Fraction (AIM HIGHer) | 2024 |
| 2024-06-06 | Medtronic, Inc. | $745 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | SMART Trial | 2024 |
| 2024-06-06 | Medtronic, Inc. | $745 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | SMART Trial | 2024 |
| 2024-06-06 | PFIZER INC. | $117 | Research payment | Cash or cash equivalent | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED | 2024 | |
| 2024-06-05 | Impulse Dynamics (USA) Inc. | $5,250 | Research payment | Cash or cash equivalent | OPTIMIZER Device, Cardiovascular Device | Assessment of CCM in HF With Higher Ejection Fraction (AIM HIGHer) | 2024 |
| 2024-06-05 | Impulse Dynamics (USA) Inc. | $2,750 | Research payment | Cash or cash equivalent | OPTIMIZER Device, Cardiovascular Device | Post Approval Study (PAS) of the OPTIMIZER Smart and CCM Therapy | 2024 |
| 2024-06-05 | Genentech, Inc. | $1,500 | Research payment | Cash or cash equivalent | MyTACTIC Targeting Actionable Mutation Study in Cancer US PIIa multicenter nonrandomized open LBL | 2024 | |
| 2024-06-05 | Genentech, Inc. | $1,500 | Research payment | Cash or cash equivalent | MyTACTIC Targeting Actionable Mutation Study in Cancer US PIIa multicenter nonrandomized open LBL | 2024 | |
| 2024-06-04 | Genetesis, Inc. | $14,483 | Research payment | Cash or cash equivalent | CardioFlux Device, Cardiovascular Diagnostic | MCG for Suspected INOCA Confirmed by Thermodilution-Derived CFR (Micro(T)) | 2024 |
| 2024-06-04 | PFIZER INC. | $6,590 | Research payment | Cash or cash equivalent | PREVNAR 20 Biological, VACCINES | A PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A | 2024 |
| 2024-06-04 | ERBE USA Inc | $5,000 | Honoraria | Cash or cash equivalent | Vio3 APC3 Device, ELECTROSURGICAL | 2024 | |
| 2024-06-01 | PFIZER INC. | $6,144 | Research payment | Cash or cash equivalent | A PHASE 12 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCI | 2024 | |
| 2024-05-23 | Medtronic, Inc. | $20,167 | Research payment | Cash or cash equivalent | SYMPLICITY G3 Device, Renal Denervation System | SPYRAL AFFIRM | 2024 |
| 2024-05-21 | Medtronic, Inc. | $36,865 | Research payment | Cash or cash equivalent | SYMPLICITY G3 Device, Renal Denervation System | SPYRAL AFFIRM | 2024 |
| 2024-05-21 | Baxter Healthcare | $159 | Debt forgiveness | In-kind items and services | 2024 | ||
| 2024-05-17 | Genetesis, Inc. | $8,128 | Research payment | Cash or cash equivalent | CardioFlux Device, Cardiovascular Diagnostic | MCG for Suspected INOCA Confirmed by Thermodilution-Derived CFR (Micro(T)) | 2024 |
| 2024-05-16 | Impulse Dynamics (USA) Inc. | $2,979 | Research payment | Cash or cash equivalent | OPTIMIZER Device, Cardiovascular Device | Assessment of CCM in HF With Higher Ejection Fraction (AIM HIGHer) | 2024 |
| 2024-05-15 | Penumbra, Inc. | $138 | Research payment | Cash or cash equivalent | Indigo System Device, Peripheral Intervention | STRIKE-PE | 2024 |
| 2024-05-06 | Genetesis, Inc. | $3,783 | Research payment | Cash or cash equivalent | CardioFlux Device, Cardiovascular Diagnostic | MCG for Suspected INOCA Confirmed by Thermodilution-Derived CFR (Micro(T)) | 2024 |
| 2024-05-04 | PFIZER INC. | $1,375 | Research payment | Cash or cash equivalent | PREVNAR 20 Biological, VACCINES | A PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A | 2024 |
| 2024-05-04 | PFIZER INC. | $1,226 | Research payment | Cash or cash equivalent | A PHASE 12 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCI | 2024 | |
| 2024-05-02 | Olympus Corporation of the Americas | $4,000 | Grant | Cash or cash equivalent | 2024 | ||
| 2024-04-26 | PFIZER INC. | $5,686 | Research payment | Cash or cash equivalent | PREVNAR 20 Biological, VACCINES | A PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A | 2024 |
| 2024-04-26 | PFIZER INC. | $4,660 | Research payment | Cash or cash equivalent | A PHASE 12 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCI | 2024 | |
| 2024-04-25 | PFIZER INC. | $4,330 | Research payment | Cash or cash equivalent | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED | 2024 | |
| 2024-04-23 | Penumbra, Inc. | $250 | Research payment | Cash or cash equivalent | Indigo System Device, Peripheral Intervention | STRIKE-PE | 2024 |
| 2024-04-18 | BIOTRONIK INC. | $250 | Research payment | Cash or cash equivalent | Siello Device, Cardiology/Vascular Diseases | SIELLO | 2024 |
| 2024-04-18 | BIOTRONIK INC. | $250 | Research payment | Cash or cash equivalent | Siello Device, Cardiology/Vascular Diseases | SIELLO | 2024 |
| 2024-04-18 | BIOTRONIK INC. | $212 | Research payment | Cash or cash equivalent | Protego S 65 Device, Cardiology/Vascular Diseases | Protego DF4 | 2024 |
| 2024-04-18 | BIOTRONIK INC. | $212 | Research payment | Cash or cash equivalent | Protego S 65 Device, Cardiology/Vascular Diseases | Protego DF4 | 2024 |
| 2024-04-18 | BIOTRONIK INC. | $212 | Research payment | Cash or cash equivalent | Siello Device, Cardiology/Vascular Diseases | SIELLO | 2024 |
| 2024-04-18 | BIOTRONIK INC. | $212 | Research payment | Cash or cash equivalent | Siello Device, Cardiology/Vascular Diseases | SIELLO | 2024 |
| 2024-04-18 | BIOTRONIK INC. | $212 | Research payment | Cash or cash equivalent | Protego S 65 Device, Cardiology/Vascular Diseases | Protego DF4 | 2024 |
| 2024-04-17 | Impulse Dynamics (USA) Inc. | $3,684 | Research payment | Cash or cash equivalent | OPTIMIZER Device, Cardiovascular Device | Assessment of CCM in HF With Higher Ejection Fraction (AIM HIGHer) | 2024 |
| 2024-04-17 | Genentech, Inc. | $2,819 | Research payment | Cash or cash equivalent | MyTACTIC Targeting Actionable Mutation Study in Cancer US PIIa multicenter nonrandomized open LBL | 2024 | |
| 2024-04-17 | Takeda Pharmaceuticals U.S.A., Inc. | $2,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2024 | ||
| 2024-04-17 | Impulse Dynamics (USA) Inc. | $75 | Research payment | Cash or cash equivalent | OPTIMIZER Device, Cardiovascular Device | Post Approval Study (PAS) of the OPTIMIZER Smart and CCM Therapy | 2024 |
| 2024-04-12 | Impulse Dynamics (USA) Inc. | $19,200 | Research payment | Cash or cash equivalent | OPTIMIZER Device, Cardiovascular Device | Assessment of CCM in HF With Higher Ejection Fraction (AIM HIGHer) | 2024 |
| 2024-04-12 | Boston Scientific Corporation | $5,000 | Grant | Cash or cash equivalent | Device, General - Therapies_ENDO | 2024 | |
| 2024-04-12 | Boston Scientific Corporation | $2,000 | Grant | In-kind items and services | Device, General - Therapies_ENDO | 2024 | |
| 2024-04-11 | Medtronic, Inc. | $225 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | TAVR Low Risk | 2024 |
| 2024-04-11 | Medtronic, Inc. | $225 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | TAVR Low Risk | 2024 |
| 2024-04-06 | ERBE USA Inc | $2,000 | Education | Cash or cash equivalent | Vio3 APC3 Device, Gastroenterology | 2024 | |
| 2024-04-05 | PFIZER INC. | $6,590 | Research payment | Cash or cash equivalent | PREVNAR 20 Biological, VACCINES | A PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A | 2024 |
| 2024-04-05 | PFIZER INC. | $772 | Research payment | Cash or cash equivalent | A PHASE 12 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCI | 2024 | |
| 2024-04-03 | Medtronic, Inc. | $605 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | CoreValve SURTAVI | 2024 |
| 2024-04-03 | Medtronic, Inc. | $605 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | CoreValve SURTAVI | 2024 |
| 2024-04-03 | Genentech, Inc. | $440 | Research payment | Cash or cash equivalent | TNKase Biological, Metabolism & Primary Care | Tenecteplase in stroke patients between 4 5 and 24 hours | 2024 |
| 2024-04-02 | Medtronic, Inc. | $1,388 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | EXPAND II | 2024 |
| 2024-04-02 | Medtronic, Inc. | $1,388 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | EXPAND II | 2024 |
| 2024-04-02 | Medtronic, Inc. | $500 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | EXPAND II | 2024 |
| 2024-04-02 | Medtronic, Inc. | $500 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | EXPAND II | 2024 |
| 2024-03-29 | PFIZER INC. | $2,373 | Research payment | Cash or cash equivalent | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED | 2024 | |
| 2024-03-29 | Penumbra, Inc. | $250 | Research payment | Cash or cash equivalent | Indigo System Device, Peripheral Intervention | STRIKE-PE | 2024 |
| 2024-03-28 | PFIZER INC. | $2,122 | Research payment | Cash or cash equivalent | AN INTERVENTIONAL PHASE 23 ADAPTIVE MULTICENTER RANDOMIZED DOUBLEBLIND STUDY TO INVESTIGATE EFFICACY AND SAFETY OF ORAL | 2024 | |
| 2024-03-27 | Penumbra, Inc. | $2,500 | Research payment | Cash or cash equivalent | Indigo System Device, Peripheral Intervention | STRIKE-PE | 2024 |
| 2024-03-26 | PFIZER INC. | $5,886 | Research payment | Cash or cash equivalent | PREVNAR 20 Biological, VACCINES | A PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A | 2024 |
| 2024-03-26 | PFIZER INC. | $3,028 | Research payment | Cash or cash equivalent | A PHASE 12 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCI | 2024 | |
| 2024-03-25 | Takeda Pharmaceuticals U.S.A., Inc. | $2,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2024 | ||
| 2024-03-22 | Medtronic, Inc. | $500 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | SMART Trial | 2024 |
| 2024-03-22 | Medtronic, Inc. | $500 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | SMART Trial | 2024 |
| 2024-03-21 | Regeneron Healthcare Solutions, Inc. | $2,000 | Grant | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | 2024 | |
| 2024-03-21 | Regeneron Healthcare Solutions, Inc. | $2,000 | Grant | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | 2024 | |
| 2024-03-21 | Regeneron Healthcare Solutions, Inc. | $2,000 | Grant | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | 2024 | |
| 2024-03-20 | Olympus America Inc. | $1,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | HANAROSTENT Biliary (NNN) Device, Endotherapy | 2024 | |
| 2024-03-20 | Olympus America Inc. | $1,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | HANAROSTENT Biliary (NNN) Device, Endotherapy | 2024 | |
| 2024-03-15 | PFIZER INC. | $1,633 | Research payment | Cash or cash equivalent | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED | 2024 | |
| 2024-03-15 | Medtronic, Inc. | $440 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | SMART Trial | 2024 |
| 2024-03-15 | Medtronic, Inc. | $440 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | SMART Trial | 2024 |
| 2024-03-14 | Penumbra, Inc. | $2,876 | Research payment | Cash or cash equivalent | Indigo System Device, Peripheral Intervention | STRIKE-PE | 2024 |
| 2024-03-13 | Biogen, Inc. | $10,515 | Research payment | Cash or cash equivalent | Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Phase 3 Study to Evaluate the Efficacy and Sa | 2024 | |
| 2024-03-13 | ACUMED LLC | $2,000 | Grant | Cash or cash equivalent | 2024 | ||
| 2024-03-06 | PFIZER INC. | $31,187 | Research payment | Cash or cash equivalent | A PHASE 12 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCI | 2024 | |
| 2024-03-06 | PFIZER INC. | $14,647 | Research payment | Cash or cash equivalent | PREVNAR 20 Biological, VACCINES | A PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A | 2024 |
| 2024-03-01 | Genetesis, Inc. | $9,700 | Research payment | Cash or cash equivalent | CardioFlux Device, Cardiovascular Diagnostic | MCG for Suspected INOCA Confirmed by Thermodilution-Derived CFR (Micro(T)) | 2024 |
| 2024-02-28 | ABBVIE INC. | $2,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | LINZESS Drug, GASTROENTEROLOGY | 2024 | |
| 2024-02-27 | PFIZER INC. | $3,500 | Research payment | Cash or cash equivalent | AN INTERVENTIONAL PHASE 23 ADAPTIVE MULTICENTER RANDOMIZED DOUBLEBLIND STUDY TO INVESTIGATE EFFICACY AND SAFETY OF ORAL | 2024 | |
| 2024-02-27 | PFIZER INC. | $1,576 | Research payment | Cash or cash equivalent | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED | 2024 | |
| 2024-02-22 | ABBVIE INC. | $2,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | SKYRIZI Biological, IMMUNOLOGY | 2024 | |
| 2024-02-21 | Impulse Dynamics (USA) Inc. | $3,432 | Research payment | Cash or cash equivalent | OPTIMIZER Device, Cardiovascular Device | Post Approval Study (PAS) of the OPTIMIZER Smart and CCM Therapy | 2024 |
| 2024-02-21 | Impulse Dynamics (USA) Inc. | $220 | Research payment | Cash or cash equivalent | OPTIMIZER Device, Cardiovascular Device | Assessment of CCM in HF With Higher Ejection Fraction (AIM HIGHer) | 2024 |
| 2024-02-16 | PFIZER INC. | $9,100 | Research payment | Cash or cash equivalent | ABRYSVO Biological, VACCINES | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNI | 2024 |
| 2024-02-15 | Penumbra, Inc. | $1,490 | Research payment | Cash or cash equivalent | Indigo System Device, Peripheral Intervention | STRIKE-PE | 2024 |
| 2024-02-14 | Endologix LLC | $1,950 | Research payment | Cash or cash equivalent | ENDOCROSS Device Device, Cardiology/Vascular Diseases | Detour II Study | 2024 |
| 2024-02-12 | Impulse Dynamics (USA) Inc. | $4,250 | Research payment | Cash or cash equivalent | OPTIMIZER Device, Cardiovascular Device | Post Approval Study (PAS) of the OPTIMIZER Smart and CCM Therapy | 2024 |
| 2024-02-12 | Impulse Dynamics (USA) Inc. | $3,264 | Research payment | Cash or cash equivalent | OPTIMIZER Device, Cardiovascular Device | Post Approval Study (PAS) of the OPTIMIZER Smart and CCM Therapy | 2024 |
| 2024-02-09 | PFIZER INC. | $20,944 | Research payment | Cash or cash equivalent | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED | 2024 | |
| 2024-02-08 | PFIZER INC. | $12,500 | Research payment | Cash or cash equivalent | AN INTERVENTIONAL PHASE 23 ADAPTIVE MULTICENTER RANDOMIZED DOUBLEBLIND STUDY TO INVESTIGATE EFFICACY AND SAFETY OF ORAL | 2024 | |
| 2024-02-06 | PFIZER INC. | $7,265 | Research payment | Cash or cash equivalent | A PHASE 12 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCI | 2024 | |
| 2024-02-06 | PFIZER INC. | $6,319 | Research payment | Cash or cash equivalent | PREVNAR 20 Biological, VACCINES | A PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A | 2024 |
| 2024-02-01 | Medtronic, Inc. | $600 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | TAVR Low Risk | 2024 |
| 2024-02-01 | Medtronic, Inc. | $600 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | TAVR Low Risk | 2024 |
| 2024-01-31 | Medtronic, Inc. | $500 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | EXPAND II | 2024 |
| 2024-01-31 | Medtronic, Inc. | $500 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | EXPAND II | 2024 |
| 2024-01-26 | PFIZER INC. | $39,634 | Research payment | Cash or cash equivalent | A PHASE 12 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCI | 2024 | |
| 2024-01-26 | PFIZER INC. | $13,296 | Research payment | Cash or cash equivalent | PREVNAR 20 Biological, VACCINES | A PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A | 2024 |
| 2024-01-26 | PFIZER INC. | $5,675 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | A PHASE 23 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VACCINE CANDIDATES FO | 2024 |
| 2024-01-25 | Medtronic, Inc. | $600 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | CoreValve SURTAVI | 2024 |
| 2024-01-25 | Medtronic, Inc. | $600 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | CoreValve SURTAVI | 2024 |
| 2024-01-23 | Impulse Dynamics (USA) Inc. | $300 | Research payment | Cash or cash equivalent | OPTIMIZER Device, Cardiovascular Device | Assessment of CCM in HF With Higher Ejection Fraction (AIM HIGHer) | 2024 |
| 2024-01-21 | Medtronic, Inc. | $250 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | SMART Trial | 2024 |
| 2024-01-21 | Medtronic, Inc. | $250 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | SMART Trial | 2024 |
| 2024-01-19 | Medtronic, Inc. | $5,833 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | EXPAND II | 2024 |
| 2024-01-19 | Medtronic, Inc. | $5,833 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | EXPAND II | 2024 |
| 2024-01-19 | Medtronic, Inc. | $2,208 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | SMART Trial | 2024 |
| 2024-01-19 | Medtronic, Inc. | $2,208 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | SMART Trial | 2024 |
| 2024-01-18 | Medtronic, Inc. | $892 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | TAVR Low Risk | 2024 |
| 2024-01-18 | Medtronic, Inc. | $892 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | TAVR Low Risk | 2024 |
| 2024-01-17 | Genentech, Inc. | $10,822 | Research payment | Cash or cash equivalent | MorningSun | 2024 | |
| 2024-01-17 | Genentech, Inc. | $2,760 | Research payment | Cash or cash equivalent | MorningSun | 2024 | |
| 2024-01-17 | Genentech, Inc. | $2,070 | Research payment | Cash or cash equivalent | MorningSun | 2024 | |
| 2024-01-17 | AngioDynamics, Inc. | $577 | Long term medical supply or device loan | In-kind items and services | Solero Device, Oncology | 2024 | |
| 2024-01-17 | Medtronic, Inc. | $280 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | CoreValve SURTAVI | 2024 |
| 2024-01-17 | Medtronic, Inc. | $280 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | CoreValve SURTAVI | 2024 |
| 2024-01-10 | PFIZER INC. | $900 | Research payment | Cash or cash equivalent | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED | 2024 | |
| 2024-01-06 | PFIZER INC. | $6,862 | Research payment | Cash or cash equivalent | PREVNAR 20 Biological, VACCINES | A PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A | 2024 |
| 2024-01-06 | PFIZER INC. | $5,983 | Research payment | Cash or cash equivalent | A PHASE 12 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCI | 2024 | |
| 2024-01-03 | Eli Lilly and Company | $15,050 | Research payment | Cash or cash equivalent | STUDY OF LOXO-305 VERSUS INVESTIGATOR'S CHOICE (IDELAR OR BR) IN PATIENTS WITH PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LE | 2024 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Detroit, MI, county Wayne County, MI, state Michigan; placed by its city name.
| Measure | Place (city or town) Detroit, MI | County Wayne County, MI | State Michigan |
|---|---|---|---|
| Population B01003 | 638,530 | 1,772,259 | 10,077,761 |
| Population, 2020 census P1 | 639,111 | 1,793,561 | 10,077,331 |
| Median age B01002 | 35.2 | 37.9 | 40.2 |
| Under 18 B01001 | 24.8% | 23.6% | 21.2% |
| 65 and over B01001 | 15.1% | 16.6% | 18.6% |
| Households B11001 | 257,998 | 700,591 | 4,076,369 |
| Foreign born B05002 | 6.6% | 10.3% | 7.2% |
| Median household income B19013 | $39,938 | $60,539 | $72,875 |
| Median family income B19113 | $49,398 | $79,522 | $93,357 |
| Per capita income B19301 | $24,594 | $34,906 | $40,735 |
| Poverty rate B17001 | 32.7% | 20.8% | 13.2% |
| Unemployment rate B23025 | 14.0% | 8.7% | 5.7% |
| Civilian labor force B23025 | 268,955 | 828,838 | 5,018,449 |
| Mean commute (minutes) B08013 | 24.8 | 24.7 | 24.2 |
| Bachelor's degree or higher B15003 | 18.1% | 27.6% | 32.4% |
| Housing units B25001 | 329,393 | 801,083 | 4,622,236 |
| Owner-occupied B25003 | 50.3% | 64.8% | 73.2% |
| Renters B25003 | 49.7% | 35.2% | 26.8% |
| Median home value B25077 | $83,900 | $178,500 | $231,600 |
| Median gross rent B25064 | $1,074 | $1,132 | $1,129 |
| White, not Hispanic B03002 | 10.8% | 47.9% | 72.4% |
| Black B03002 | 75.0% | 36.6% | 13.1% |
| Hispanic or Latino B03002 | 8.3% | 6.9% | 5.9% |
| Asian B03002 | 1.7% | 3.7% | 3.4% |
| American Indian and Alaska Native B03002 | 0.2% | 0.2% | 0.3% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Detroit, MI.
Comments